Phosphorylation of key proteins can have profound effects on normal and diseased protein interaction networks. Breast tumor kinase (BRK) is a non-receptor protein tyrosine kinase that is up-regulated in ~80% of invasive ductal breast tumors. During a search for signaling pathways regulated by BRK we found that BRK binds and phosphorylates SMAD4, and regulates components of the TGF-β/ SMAD4 signaling pathway. Tyrosine phosphorylated SMAD4 suppresses signaling pathways involved in cell homeostasis and apoptosis and upregulates several oncogenic signaling cascades. A constitutively active BRK mutant, BRK-Y447F, phosphorylates SMAD4 resulting in its recognition by the ubiquitin-proteasome system, which accelerates SMAD4 degradation. In addition, activated BRK reorganizes a SMAD4 associated protein interaction network where phosphorylated SMAD4 interacts with several chromatin modifying complexes. Activated BRK rewiring of SMAD4 protein-protein interactions cause a wider genome accessibility resulting in repression of tumor suppressor genes like FRK. Our findings indicated that BRK targeting of SMAD4 has several biochemical and cellular consequences including the regulation of chromatin modifying complexes and potential promotion of epithelial-to-mesenchymal transition.
Introduction
Breast tumor kinase (BRK) is a non-receptor tyrosine kinase highly expressed in most breast cancer cell lines and tumors 1 . It displays a similar architecture and 30-40% sequence identity with Src Family Kinases (SFKs) 2 . It is composed of an Src homology 3 domain (SH3 domain), an SH2 domain, and a catalytic tyrosine kinase domain 3 . Like Src, BRK is negatively regulated by phosphorylation of its C-terminal tyrosine 447 and activated by phosphorylation of tyrosine 342 in the catalytic domain 4, 5 . Mutation of tyrosine 447 to phenylalanine significantly enhances the kinase activity of BRK 4, 5 .
BRK has been implicated in several signaling cascades, notably in mitogenic signaling 6 .
It has been shown to enhance the mitogenic signals of EGF by promoting the activation of Akt 7 .
Various EGFR ligands, including EGF and heregulin, have been shown to stimulate BRK activity, resulting in increased cell proliferation and migration [7] [8] [9] . Consistent with this, BRK has been shown to promote HER2-induced tumorigenesis in orthotropic transplantation-based models 10 . We have also reported that BRK activation significantly enhances tumor formation in xenograft models 5 . Additionally, BRK is overexpressed in over 80% of breast carcinomas 1 , and in many other major cancer types including lung 11 , ovarian 12 , and pancreatic 13 cancers. Although the cellular role of BRK in carcinogenesis has been established, its role in controlling signal transduction pathways is still unclear.
Here, we first used a kinome array 14 to elucidate the role of BRK in regulating signal transduction pathways and identified components of the TGF-β/SMAD signaling pathway as candidate BRK targets. Although the major molecular components of the TGF-β/SMAD signaling pathway are known 15 , the dynamics of TGF-β/SMAD signaling remains unclear in many systems, including normal and cancer cells. Current evidence supports that upon TGFβ/BMP receptor activation, SMAD2, and SMAD3 or SMAD1, SMAD5 and SMAD8 bind SMAD4 forming SMAD complexes which translocate into the nucleus to initiate gene regulation 16, 17 . These SMAD complexes can either recruit chromatin remodeling complex SWI/SNF, mediator, and histone acetyltransferases (HATs) to activate transcription, or recruit chromatin modifying complex SIN3/histone deacetylase (HDAC) for transcriptional repression of target genes 18, 19 .
we expressed GFP-SMAD2/3/4 either alone or with BRK-YF into HEK 293 cells followed by immunoprecipitation using antibodies against GFP and BRK. We found that BRK-YF copurified with either SMAD2, SMAD3, or SMAD4 (Figure 2A) . A reciprocal association was also observed when BRK-YF was co-expressed with either GFP-SMAD2/3/4 and immunoprecipitated with anti-BRK antibody (Figure 2B) . Since all three of the SMAD proteins (GFP-SMAD2/3/4) interacted with BRK-YF, we next determined which of them, if any, had the strongest interaction with BRK. We co-expressed GFP-SMAD2/3/4 together with BRK-YF in HEK 293 cells and immunoprecipitated proteins from the resulting whole cell lysates with an anti-BRK antibody. We then analyzed these proteins by immunoblotting with specific antibodies against SMAD2, SMAD3, and SMAD4. We detected SMAD4 but neither SMAD2 nor SMAD3 in the BRK purified sample, suggesting that in the presence of all three SMAD proteins, SMAD4 competitively binds BRK-YF, possibly indicating a stronger affinity of SMAD4 towards BRK-YF ( Figure 2C) .
Next, to map the domains of BRK important for interaction with SMAD4, we ectopically expressed five BRK mutants with GFP-SMAD4 in HEK 293 cells. These included three mutants affecting the Src Homology domains: BRK-W44A; ΔSH2-BRK, which lacks the SH2 domain; and ΔSH3-BRK, which lacks the SH3 domain. Additionally, we used two mutants to assess whether BRK activity was necessary for interaction: the kinase-inactive BRK-Y342A and the constitutively active BRK-YF. We observed that BRK-W44A, ΔSH2-BRK, BRK-WT, BRK-Y342A, and BRK-Y447F all co-precipitated with GFP-SMAD4. In contrast, ΔSH3-BRK did not co-precipitate with GFP-SMAD4, suggesting that the SH3 domain is necessary for BRK/SMAD4 interaction (Figure 2D) . In a similar fashion, we mapped domains of SMAD4 essential for interaction with BRK. We expressed BRK-YF in HEK293T cells together with fulllength (FL) Halo-SMAD4 or with several SMAD4 truncation mutants (described in Figure 2E) and captured protein complexes by Halo affinity purification. We found SMAD4 mutants that contained either the MH1 domain or the MH2 domain (mutants A, B, D, and E) interacted with BRK-YF. The MH1 domain showed higher affinity for BRK-YF than the MH2 domain (compare Figure 2E, lanes B, and D) , while the linker region alone showed a very weak affinity for BRK-YF (Figure 2E , lane C). Protein interactions were further analyzed by affinity purification followed by mass spectrometry (APMS) of Halo-SMAD4 ectopically expressed by itself or co-expressed with either SNAP-Flag-BRK-WT or SNAP-Flag-BRK-YF in HEK293T cells. Halo affinity purification followed by MudPIT proteomics analyses showed that Halo-SMAD4 was expressed at similar levels in those cells (Suppl. Figure S2A) and was able to pull down both BRK-WT and BRK-YF ( Figure 2F) . The interaction was shown to be reciprocal when SNAP-Flag-BRK-YF copurified with Halo-SMAD4 in the SNAP affinity purification analyzed by MudPIT (Suppl. Fig. 2B) . These APMS experiments hence confirmed the conclusion from the co-immunoprecipitation experiments: BRK interacts with SMAD4.
Next, we examined whether Halo-SMAD4 and SNAP-Flag-BRK-YF co-localize in vivo.
We used live cell imaging to assess the localization of ectopically expressed Halo-SMAD4 and SNAP-FLAG-BRK-YF in HEK 293T cells. Halo-SMAD4 and SNAP-Flag-BRK-YF were transfected in HEK 293T cells either alone or together and were imaged by confocal microscopy (Figure 2G) . We observed that Halo-SMAD4 predominantly localized to the cytosol ( observations support that SMAD4 is a cytosolic BRK interaction partner in cells, which is consistent with a potential role of SMAD4 as a target of BRK phosphorylation.
Activated BRK phosphorylates SMAD4 on residues Tyr 353 and Tyr 412
We have shown that activated BRK interacts with SMAD4 and colocalizes with SMAD4 in the cytosol of live cells. Given that BRK is a non-receptor tyrosine kinase, we asked whether activated BRK phosphorylates SMAD4. To selectively identify BRK-mediated SMAD4 phosphorylation, we expressed Halo-SMAD4 alone or in combination with SNAP-Flag-BRK-YF in HEK 293T cell and affinity purified SMAD4 to analyze post-translational modifications (PTMs) by mass spectrometry (Figure 3A) . Although prior studies had reported several serine, threonine, and tyrosine phosphorylation sites within SMAD4 ( Figure 3B and not shown; source: PhosphoSitePlus®), our MudPIT-APMS approach identified several novel phosphorylation sites on SMAD4 in the presence or absence of SNAP-Flag-BRK-YF (Suppl . Table 1 ). Interestingly, we found that Halo-SMAD4 displayed three unique phosphorylations on S344, Y353, and Y412
in the presence of activated BRK (Figure 3B) . Surprisingly, one of these phosphorylation sites was Serine 344, which raises the intriguing possibility that activated BRK may be a dualspecificity kinase like MEK kinases, which are involved in MAP pathways 25 . Nonetheless, since BRK is a tyrosine kinase, we focused to further validate the phosphorylation of Y353 and Y412 ( Figure 3B ). We implemented a multiple reaction monitoring (MRM) approach to specifically target the peptides bearing these phosphorylated tyrosines (Figure 3C and Suppl. Fig. 3A-B ).
For both phosphorylated sites, the transitions of at least four fragment ions bearing the modified residues were targeted for MRM ( Figure 3C ) and were detected in the protein sample from the affinity-purified Halo-SMAD4 co-transfected with BRK-YF ( Figure 3C) . Additionally, the MS/MS spectra that were acquired immediately after the MRM spectra mapped to the expected phosphorylated peptides (Suppl. Fig. S3A-B) .
To further validate BRK-mediated phosphorylation of SMAD4 Y353 and Y412, we next generated a mutant of SMAD4 lacking these two tyrosine residues (Halo-SMAD4 Y353F & Y412F). We first affinity purified Halo-SMAD4 from cells co-expressing BRK-YF with Halo-SMAD4 and analysed the pulled-down proteins with an antibody specific to phosphorylated tyrosines, PY20 (Figure 3D , left panel). We detected phosphorylated SMAD4 in the presence of BRK-YF, but not in the absence of BRK-YF. Repeating this experiment on the mutant Halo-SMAD4 Y353F & Y412F protein, we could not detect a similar band indicating phosphorylated SMAD4 (Figure 3D , right panel). Our mass spectrometry analysis of phosphorylated peptides from SMAD4 co-expressed with activated BRK-YF hence revealed two novel tyrosine residues phosphorylated explicitly by BRK. These sites were confirmed as phosphorylated with an orthogonal MRM mass spectrometry approach and by site-directed mutagenesis combined with Western blotting. These two tyrosines are located within SMAD4 MH2 domain, which is the most frequently mutated in cancers, and are likely involved in regulating the SMAD4 protein interaction network.
BRK and SMAD4 protein expression levels are inversely correlated in most breast cancer cells and tissues
Since SMAD4 is a tumor suppressor 20, 16 and we and others have previously shown that BRK acts as an oncogene 5, 13, 9 , we opted to explore the possible connection between SMAD4 and BRK protein levels in breast cancer cells and tissues. First, we examined the endogenous protein expression of SMAD4 and BRK to determine the expression profiles of these proteins in breast cancer cells. Using antibodies against each protein, we evaluated the expression level of SMAD4 and BRK in a panel of 10 breast cancer cells, two immortalized cell lines commonly used to model non-diseased human mammary epithelial cells (MCF-10A and MCF-12F), and lastly in HEK 293 cells. We detected SMAD4 in MCF-10A, MCF-12F, and HEK293, as well as in 6 breast cancer cell lines MDA231, Hs578T, T47D, BT549, MCF7, BT474. SMAD4 expression was very low or undetectable in four other breast cancer cell lines: BT20, HCC1428, SKBR3, and HCC1954 (Figure 4A) . Detectable amounts of BRK were observed in BT20, HCC1428, SKBR3, T47D, MCF7, BT474, and HCC1954, but not in MDA231, Hs578T, BT549, and HEK 293 cells, while very low expression was observed in MCF10A and MCF12F ( Figure   4A ). Interestingly, the levels of SMAD4 and BRK were inversely correlated in MCF-10A, MCF-12F, MDA MB 231, BT20, HCC1428, SKBR3, Hs578T, BT549, HCC1954, and HEK 293. In particular, the expression of SMAD4 and BRK in all of the triple negative breast cancer (TNBC) cells we tested (MDA231, BT20, Hs578T, BT549, and HCC1954) showed this inverse expression pattern ( Figure 4A) .
These diverse patterns of BRK/SMAD4 protein levels might be explained by differences in BRK or SMAD4 mRNA levels. To compare the gene expression pattern of SMAD4 and BRK, we examined RNAseq data from The Cancer Cell Line Encyclopedia (CCLE, https://portals.broadinstitute.org/ccle) corresponding to the 10 breast cancer cell lines that we had analysed. Surprisingly, we observed that SMAD4 and BRK showed similar patterns of mRNA expression in all 10 breast cancer lines including TNBC cells (Figure 4B ), suggesting that the effects we had initially noticed were likely regulated at the protein level rather than mRNA expression. Next, to reinforce the evidence obtained using cancer cell lines, we mined data from patient tumor samples 26 to determine SMAD4 and BRK protein expression patterns in three major breast cancer subtypes: Estrogen/Progesterone (ER/PR) positive, Human epidermal growth factor receptor 2 (HER2) positive, and triple negative breast cancer (TNBC). Again, we observed that SMAD4 and BRK were inversely expressed in these breast cancer subtypes ( Figure 4C) .
To further interrogate the relationship between SMAD4 and BRK expression, we stablyexpressed constitutively-active BRK (BRK-YF) into three cell lines that expressed SMAD4 but not BRK (HEK 293, MDA-MB 231 and MCF10A cell lines). An elevated level of phosphorylation of cellular targets was observed in the cells stably expressing GFP-BRK-YF, as visualized by immunoblotting with an anti-phosphotyrosine antibody (4G10) ( Figure 4D) . We, therefore, examined the expression of SMAD4 in BRK-YF expressing cells and observed a sharp reduction of endogenous SMAD4 protein in all three of the cell lines expressing activated BRK compared to those parental cells ( Figure 4D ). However, we did not observe any noticeable change in the endogenous protein levels of SMAD2 and SMAD3 (Figure 4D ), suggesting that the effect that activated BRK had on protein levels was specific to SMAD4.
Finally, since our data showed that SMAD4 and BRK protein levels were inversely correlated, we asked whether knocking down BRK by short hairpin RNA (shRNA) could modulate the levels of SMAD4 in MCF7 cells. MCF7 cells were selected because both SMAD4 and BRK proteins were moderately expressed in these cells ( Figure 4A ). We attained a 70-80% reduction of BRK in MCF7 cells ( Figure 4E ). However, we did not observe any noticeable effect on the expression of SMAD4 protein in MCF7 cells with depleted BRK (Figure 4E ).
Since the depletion of BRK did not affect the expression of SMAD4, we aimed to assess the expression of a known target of SMAD4 in GFP-BRK-YF cells. As a proof of principle, we evaluated the expression of p21, a known target of SMAD4 15, 27 , in the cells stably expressing GFP-BRK-YF and the parental cell lines. We found that p21 protein levels sharply decreased in the cells expressing activated BRK compared to parental cells ( Figure 4F) . Moreover, reduction of p21 induced by constitutively active BRK-YF could be rescued by ectopically overexpressed GFP-SMAD4 ( Figure 4F ), suggesting that large amounts of the GFP-SMAD4 compensated for the degradation of endogenous SMAD4 mediated by BRK-YF phosphorylation, hence restoring the downstream expression of the p21 protein.
Overall, our data indicate that, compared with control cells, the increased levels of BRK observed in several breast cancer cell types was concomitant with reduced levels of SMAD4, and that changes in protein level did not necessarily result from changes in BRK/SMAD4 mRNA levels. Additionally, introducing the active BRK-YF into cells expressing SMAD4 resulted in reduced levels of SMAD4. As BRK and SMAD4 showed similar mRNA expression patterns but differ in protein levels, it is possible that BRK suppresses SMAD4 through the ubiquitin/proteasome pathway.
SMAD4 interacts with chromatin-modifying complexes and ubiquitin modification enzymes in a manner dependent on activated BRK
Since BRK phosphorylates SMAD4 and regulates SMAD4 protein levels, we considered that BRK might also be influencing interactions between SMAD4 and other cellular proteins, possibly ubiquitin modifying enzymes and other components of TGF-β/BMP signaling pathways. To interrogate the impact of constitutively active BRK on SMAD4 associated proteins, we used our established workflow 28 for Halo/MudPIT APMS analysis (Suppl. Fig.   S4A ). We first expressed Halo-SMAD4 in the presence or absence of SNAP-Flag-BRK-WT or SNAP-Flag-BRK-YF and purified Halo-SMAD4 associated proteins by affinity chromatography. We next identified SMAD4 associated proteins by MudPIT mass spectrometry (Suppl. Fig. S4B-D) . The proteins that we found significantly enriched (log2FC ≥ 2, FDR ≤ 0.05) with Halo-SMAD4 either alone or with BRK or BRK-YF (Suppl. Fig. S4E ) were assembled into an interaction network (Suppl. Fig. S4F ). First, we found that only four proteins co-purified with SMAD4 both in the presence or absence of BRK/BRK-YF (Suppl. Fig. S4E ).
Interestingly, three of these proteins are core components of TGF-β/BMP signaling pathways: SMAD2 and DCP1A belong to the TGF-β pathway, while SMAD5 belongs to the BMP pathway 16 ; in addition, DCP1A is known to bind SMAD4 29 . Second, there were marked changes to the SMAD4 protein interactome when SMAD4 was co-expressed with BRK: 129 proteins copurified with SMAD4 only in the presence of BRK-YF, and a further 27 SMAD4 associated proteins were only identified in the presence of WT BRK, suggesting a possible role for different forms of BRK in modulating SMAD4 interactions. To quantitively investigate how the Halo-SMAD4 interactome changed in the presence of BRK or BRK-YF, we defined a set of 84 proteins enriched with Halo-SMAD4 (log2FC ≥ 1, FDR ≤ 0.05) and asked how the enrichment of these proteins (log2FC) changed in the presence of BRK or BRK-YF (Suppl. Fig. S5A and Suppl. Table 2 ). Mirroring the results of the first analysis, we found that WT BRK negatively regulated most Halo-SMAD4 protein associations, whereas activated BRK-YF positively regulated many Halo-SMAD4 protein associations (Suppl. Fig. S5A ).
Next, we examined the relative stoichiometry of SMAD1, 2, 3, 5 and SMAD8/9, the downstream core component of TGF-β/BMP signal transduction pathways, captured by Halo-SMAD4 in presence or absence of BRK-YF (Suppl. Fig. S5B ). Although, we had observed that BRK-YF regulated many Halo-SMAD4 protein associations (Figure S5A) , the amounts of other SMAD proteins captured by SMAD4 were not affected by the presence of activated BRK (Suppl. Fig. S5B ). We further analyzed the Halo-SMAD4 associated proteins for their involvement in canonical signaling pathways by using Ingenuity Pathways Analysis (IPA). We observed that in addition to TGF-β/BMP signaling, Halo-SMAD4 associated proteins were involved in many other signaling pathways (Suppl. Fig. S5C ). The presence of BRK-YF suppressed most of signaling pathways involved in cell death and homeostasis and strengthened the signaling pathways involved in cell differentiation and proliferation (Suppl. Fig. S5C ). Of note, Halo-SMAD4 was found to be involved in tRNA charging, pyruvate dehydrogenase complex, regulation of eIF4 and p70S6K, and EIF2 signaling pathways only in the presence of SNAP-Flag-BRK-YF (Suppl . Table 3 ). Interestingly, the above-mentioned signaling pathways are essential for uncontrolled or rapidly growing cells: for example, tRNA charging and EIF2 signaling have been shown to enhance the protein translation process to meet the increased need of cancer cells 30, 31 ; cancer cells inhibit the pyruvate dehydrogenase complex to attain aerobic glycolysis for selective growth advances 32 ; and in many cancer types, eIF4 and p70S6K signal transduction pathways are linked to cell survival and proliferation 33 .
In addition to examining the SMAD4 association with signaling proteins, we analyzed SMAD associated protein complexes using DAVID 34 . We found that Halo-SMAD4 alone interacted with members of the chaperonin-containing T-complex, nonhomologous end joining complex, and DNA replicating factor A complex ( Figure 5A and Suppl. Table 4 ). Interestingly, we found that Halo-SMAD4 interacted with components of several additional protein complexes in the presence of BRK-YF. These included several chromatin-modifying complexes: the Sin3/HDAC and NuRD histone deacetylase complexes and the NuA4 histone acetyltransferase complex ( Figure 5A and Suppl. Table 4 ). Although it was previously reported that the SMAD complex recruits both SIN3/HDAC and SWI/SNF complexes for transcriptional repression of target genes 18 , our data here suggest that SMAD4 interacts with SIN3/HDAC only in the presence of BRK-YF. The presence of BRK and BRK-mediated phosphorylation of SMAD4 might hence be required for the interaction of SMAD4 with chromatin-modifying complexes.
Since we found that SMAD4 interacted with several chromatin-modifying complexes, we asked how many core subunits of those complexes were co-purified with SMAD4 ( Figure 5B ).
We observed that several core components of the Sin3/HDAC complex (Sin3A, HDAC1, HDAC2, RBBP4, RBBP7) and several known Sin3A-associated transcription factors (FOXK1, FOXK2, and MAX) were co-purified with Halo-SMAD4. Interestingly, most of the subunits strongly interacted with Halo-SMAD4 in the presence of BRK-YF compared with Halo-SMAD4 expressed with BRK-WT or alone (Figure 5B , left panel). We also made the novel observation that SMAD4 associates with the NuRD complex (chromatin remodeler) but only in the presence of active BRK-YF (Figure 5B , middle panel). These findings suggest that the phosphorylation of SMAD4 by activated BRK significantly enhances assembly of SMAD4 with different chromatin-modifying complexes and their transcription factors.
Since we had found that BRK phosphorylates SMAD4 (Figure 3 ) and SMAD4 levels were dramatically lower in stably expressing BRK-YF cells (Figure 4D) , we next examined whether the presence of BRK-WT/BRK-YF made Halo-SMAD4 a potential target of the ubiquitin-proteasome machinery. Indeed, we found that Halo-SMAD4 recruited several ubiquitin and deubiquitin ligases in the presence of BRK-WT/ BRK-YF ( Figure 5B , right panel). SMAD4
interacted with the deubiquitin ligases USP9X, USP32, and USP7 in the presence of both BRK-WT and BRK-YF. However, SMAD4 association with the ubiquitin ligases HERC2 and RNF138 were upregulated only in the presence of BRK-YF. Since Halo-SMAD4 interacted with ubiquitin ligases in the presence of activated BRK, we then tested the possibility that the BRKmediated phosphorylation of SMAD4 facilitated its degradation through the ubiquitin/proteasome system 35 . Halo-SMAD4, BRK-YF, and HA-ubiquitin were expressed in HEK 293T cells in the combinations shown in Figure 5C and cells were treated with or without the peptide-aldehyde proteasome inhibitor MG132 (carbobenzoxyl-L-leucyl-L-leucyl-L-leucine).
We examined SMAD4 protein for ubiquitination by resolving Halo affinity purified samples by SDS-PAGE and immunoblotting the resulting Western blot using anti-HA antibody. Our data showed a smear of ubiquitin-conjugated SMAD4 in the presence of proteasome inhibitor ( Figure   5C , lane 5), which was not apparent in controls ( Figure 5C, lanes 1-4) . Our results led us to conclude that the presence of activated BRK causes the downregulation of SMAD4 by the ubiquitin/proteasome degradation pathway.
To investigate the rate of proteasomal degradation of SMAD4 in presence or absence of BRK-YF, we expressed Halo-SMAD4 in HEK 293T cells under the control of a tetracyclineinducible promoter, with or without BRK-YF. After 24 hours post-transfection, tetracyclinecontaining media was replaced with regular HEK 293T cells culture media and cells were periodically harvested as indicated in Figure 5D -E. Immunoblotting of cell lysates showed that Halo-SMAD4 protein levels were dramatically reduced in the presence of activated BRK as early as 24 hours (Figure 5E) , while in the absence of BRK-YF, Halo-SMAD4 protein levels had not significantly decreased even after 72 hours (Figure 5D) . This difference in protein stability hence consistent with a role for BRK in regulating SMAD4 degradation.
In summary, while our data indicate that deubiquitinases are recruited to SMAD4 in the presence of both BRK-WT and BRK-YF, possibly to prevent SMAD4 degradation, SMAD4 still becomes a target of HERC2 and RNF138 ubiquitin ligases in the presence of BRK-YF, leading to its degradation by the proteasome. Thus, it seems likely that SMAD4 protein levels are controlled by an interplay between SMAD4 association with deubiquitinases and ubiquitin ligases mediated by BRK.
BRK-mediated SMAD4 phosphorylation is required for its interaction with the SMAD4 signaling network and chromatin remodelers as well as its degradation.
Le Goff et al. have previously suggested that ubiquitination, but not phosphorylation, may have a role in the regulation of SMAD4 function 36 . In another study, Dupont et al. had found that Ecto/TIF1γ mediated mono-ubiquitination of SMAD4 causes the disassembly of SMAD4 from the SMAD complex and that deubiquitination by FAM/USP9x, a SMAD4 partner that we have also identified, allows SMAD4 to return to the signaling pool 37 . In this study, we have now shown that activated BRK can both phosphorylate SMAD4 and regulate its signaling network, its interaction with chromatin modifiers, and its stability (Figures 3 and 5). To gain further mechanistic insight, we again used Halo-MudPIT APMS to explore the BRK-YFmodulated SMAD4 protein-protein interaction network using a mutant of SMAD4 (Halo-SMAD4 Y353F & Y412F) that could not be phosphorylated on tyrosine residues Y353 and Y412 (Suppl. Fig. S6A ). As we have described previously with Halo-SMAD4, we analyzed protein complexes purified from cells expressing Halo-SMAD4 Y353F & Y412F with or without BRK-YF and established that baits were present at similar levels in all affinity purifications (Suppl. Fig. S6B ).
We next defined a set of proteins (the SMAD4 interactome) by pooling significant interactors identified with Halo-SMAD4 with or without BRK or BRK-YF (Figure 4B-C) , or with SMAD4 Y353F & Y412F with or without BRK-YF (Suppl. Fig. S6C-D) . Limiting our analysis to this SMAD4 interactome, we next compared the abundance of proteins captured by Halo-SMAD4 ± BRK/BRK-YF or by Halo-SMAD4 Y353F & Y412F ± BRK-YF, to the abundance of proteins captured by Halo-SMAD4 alone. These comparisons (Supplemental Table 5 ) were visualized in a heatmap and clustered (Suppl. Fig. S6E ). Consistent with our previous analyses (Figure 5) , active BRK-YF modulated Halo-SMAD4 protein interactions differently than BRK (compare Suppl. Fig. S6E, lanes 1 and 2) . In contrast, active BRK-YF did not modulate Halo-SMAD4 Y353 & 412F interactions as dramatically as it did with Halo-SMAD4 interactions (compare Suppl. Fig. S6E, lanes 2 and 4) . Exemplifying these differences, we observed a cluster of proteins (marked in black) whose interactions with SMAD4 were upregulated in all samples except SMAD4+BRK-YF and a second cluster (marked in cyan) of proteins that were upregulated only in the SMAD4+BRK-YF samples (Suppl. Fig. S6E ).
Furthermore, GO analysis for biological processes of the first cluster revealed that these proteins were mostly involved in negative regulation of apoptotic signaling, bone cell development, and spliceosomal snRNP assembly (Suppl. Fig. S6E , Treemap), while the upregulated proteins in the second cluster were mostly involved in DNA replication-independent nucleosome assembly and ubiquitination (Suppl. Fig. S6E . Treemap). This observation is consistent with a role of tyrosine phosphorylated SMAD4 in supporting fast cell growth, for example in cancer cells.
Next, we sought to find out the unique protein-protein interactions of Halo-SMAD4 phosphorylated by BRK. We found 51 proteins (circled in red in Figure 6A ) captured by BRK-YF treated Halo-SMAD4, which were not captured by the mutant Halo-SMAD4 Y353F & Y412F, which could not be phosphorylated by BRK-YF (Suppl. Table 6 ). We further used the Enrichr enrichment analysis tool 38, 39 to analyze the Jensen DISEASES database to ask if the genes coding these 51 proteins were enriched for disease-gene associations 40 , and found that most of these proteins were involved in carcinogenesis (p = 0.0025; top 20 proteins shown in Figure 6B ). Next, we interrogated the biological relevance of those Halo-SMAD4 phosphotyrosine meditated associations and, surprisingly, found that those molecules were involved in several pathways essential for highly proliferative cancer cells namely: retinoblastoma (RB) in cancer; G1 to S cell cycle control; histone modifications; DNA replication; Translation Factors;
and One-Carbon Metabolism (Figure 6C) . For example, the one-carbon metabolism pathway is required for nucleotide synthesis, methylation, and reductive metabolism, which are essential for rapidly proliferating cancer cells 41 .
While the presence of SNAP-Flag-BRK-YF did not affect the relative stoichiometry of SMAD complexes (Suppl. Figure 5B) , we examined whether the mutations of Halo-SMAD4 Y353F & Y412F showed any interference in the stoichiometry of SMAD complexes. Unlike wild-type SMAD4, the mutant SMAD4 could not bind with SMAD3 ( Figure 6D) . However, the mutations did not prevent SMAD4 binding to SMAD1, 3, 5 and SMAD8/9 (Figure 6D) , the downstream components of BMP signal transduction pathway 16 . Our findings suggest that tyrosine 353 & 412 of SMAD4 are essential for its interaction with SMAD3. Furthermore, this interaction seems to be enhanced when these tyrosines which are phosphorylated by BRK-YF in SMAD4-WT (increased recruitment of SMAD3 in SMAD4 purified from cells expressing BRK-YF compared to pull-down from parental cells).
We further interrogated whether the tyrosine phosphorylation of SMAD4 or the presence of activated BRK is required for SMAD-Sin3/HADC and SMAD-NuRD complex interactions.
Interestingly, in the presence of activated BRK, phosphorylated SMAD4 showed a stronger interaction with the Sin3/HADC complex (Figure 6E) . Next, we investigated the impact of the presence of activated BRK or activated BRK mediated tyrosine phosphorylation of SMAD4 in its interaction with ubiquitin ligases and deubiquitinases. Interestingly, we found that in the presence of the BRK-YF kinase, RNF138 (a ubiquitin ligase) interacted with Halo-SMAD4 but not with SMAD4 Y353F & Y412F, suggesting that phosphorylation of Y353 and/or Y412 is necessary for this interaction. Similarly, SMAD4 interaction with the ubiquitin ligase HERC2 was significantly augmented in the presence of activated BRK, and this interaction was completely lost with mutant Halo-SMAD4
Y353F & Y412F (Figure 6E) . Curiously, the ubiquitin ligase ITCH showed a stronger affinity for Halo-SMAD4 Y353F & Y412F in comparison to Halo-SMAD4 in the presence of activated BRK and did not interact in the absence of BRK. Considering the deubiquitinases, we noticed that USP9X and USP7 showed higher affinity for Halo-SMAD4 Y353F & Y412F in the presence of activated BRK and that the deubiquitinase USP32 interacted only with Halo-SMAD4 in the presence of activated BRK (Figure 6E) . Interestingly, like BRK, USP32 is also often overexpressed in breast cancer cells and tumors, and its inhibition reduces cell proliferation, migration, and apoptosis 42 .
Since our proteomics data (Figure 6E) showed that phosphorylation of Y353 & 412F of SMAD4 is essential for ubiquitin ligase recognition, we tested whether the mutant SMAD4 escaped BRK-regulated proteasomal degradation. Plasmids expressing Halo-SMAD4 Y353F & Y412F, SNAP-Flag-BRK-YF, and HA-ubiquitin, were transfected into HEK 293T cells. The transfected cells were treated with MG132 for 8 hours to inhibit 26S proteasome. After Halo affinity purification, we analysed purified samples for ubiquitinated proteins using an anti-HA antibody. Our data showed that ubiquitin was unable to conjugate with mutant Halo-SMAD4
Y353F & Y412F to mark it for proteasomal degradation (Figure 6F) . Our findings strongly suggest that tyrosine 353 and 412 of SMAD4 are essential for SMAD4 ubiquitination.
Since the tyrosine mutant of SMAD4 was not ubiquitinated, we next examined the stability of SMAD4 Y353F & Y412F in the presence or absence of BRK-YF. To this end, we transfected tetracycline-inducible Halo-SMAD4 Y353F & Y412F alone or with BRK-YF into HEK 293T cells. We found that Halo-SMAD4 Y353F & Y412F protein levels remained stable for a longer time in the absence of activated BRK (Figure 6G-H) . We also found that the mutant SMAD4 was more stable in the presence of BRK-YF than the WT protein (compare to Figure   5E ). These findings are consistent with a model whereby BRK-mediated phosphorylation of SMAD4 accelerates its proteasomal degradation, while the phosphorylation-incompetent SMAD4 Y353F & Y412F mutant escapes ubiquitination and subsequent degradation.
BRK represses the FRK tumor suppressor in a SMAD4-dependent manner to induce EMT and cell invasion
Since SMAD4 is a transcription factor and phosphorylated SMAD4 interacts with chromatin remodeling complexes, we next investigated genes that might be targeted by SMAD4.
We performed an in-silico analysis to identify potential SMAD4 binding sites in the genome. We found putative SMAD4-binding sites in the promoter of several genes including tumor suppressor FRK 43 . Interestingly, three putative SMAD4 binding sites were identified in the FRK promoter region (Figure 7A and Suppl. Fig. S7A ). This finding spurred our interest to further investigate a potential contection between BRK-mediated Smad4 regulation of FRK expression.
To test our hypothesis that SMAD4 regulates this promoter, we performed a luciferase reporter assay and found that luciferase activity was two-fold higher in lysates from cells co-expressing SMAD4 and the FRK promoter, suggesting that SMAD4 positively regulates the promoter activity of FRK (Figure 7B) , consistent with the presence of SMAD4 binding sites in the FRK promoter. Next, we compared the mRNA expression of FRK in MDA-MB 231 cells (which express SMAD4, but not BRK -see Figure 4A ) with FRK expression in MDA-MB 231 cells stably expressing BRK-YF. Consistent with BRK-YF-mediated degradation of SMAD4, FRK mRNA levels were very low in the cells stably expressing BRK-YF. However, overexpressing SMAD4 in the MDA 231-BRK-YF cells restored expression of FRK mRNA (Figure 7C) .
Additionally, we observed that stably expressing BRK-YF decreased the FRK protein levels in MDA 231 cells (Figure 7D, compare lanes 1 and 2) and that FRK protein levels were restored by overexpressing SMAD4 (Figure 7D ).
It has been reported that, FRK suppresses EMT and inhibits cancer metastasis 44 while TGF-β/SMAD4 signaling is crucial for EMT, and promotes metastasis 45 . We deduced that the SMAD4-dependent control of FRK expression might consequently be controlling the expression of EMT markers. To this end, we examined the expression of EMT markers (E-cadherin, Ncadherin Twist, vimentin, fibronectin, slug, and snail) in parental and BRK-YF expressing MDA-MB 231 cells. Interestingly, we found that SLUG and SNAIL expression increased in MDA-MB 231 cells stably expressing BRK-YF in comparison to parental cells (six and four folds higher respectively; Figure 7E-F) . Ectopically expressed SMAD4 suppressed the BRK-YF-mediated induction of SNAIL and SLUG (Figure 7E-F) . We did not observe any change in the other EMT markers tested (data not shown). Lastly, since our proteomics data showed that the presence of BRK-YF reduced the interaction of SMAD4 with cell adhesion molecules, we examined the cell adhesion properties of the BRK-YF expressing HEK 293 and MCF 10A cells.
Interestingly, we found that activated BRK reduced the cell adhesion capability of BRK-YF expressing cells and that adhesion capability could be completely restored by overexpressing SMAD4 (Figure 7G) . Overall, our data suggest that activated BRK induces a SMAD4-dependent suppression of tumor suppressor FRK resulting in the stimulation of EMT, and potentially metastasis (Figure 7H ).
Discussion
The cellular role of TGF-β/SMAD signaling pathway is a paradox in cancer. On the one hand, SMAD4-deficient Kras G12D pancreatic mouse models showed rapid development of pancreatic tumors 46 , while restoration of SMAD4 induced apoptosis 46 and inhibited tumorigenesis in Smad4-defective cancer cells 47 . On the other hand, knockdown of SMAD4 significantly reduced liver tumorigenesis in mice 48 . The molecular mechanism of this duality is yet to be solved. Further, it was thought that ubiquitination, but not phosphorylation, may play a role in the regulation of SMAD4 function 36 . Our current study demonstrates that activated BRK phosphorylates SMAD4 to reshape its protein interaction network which provides SMAD4 a broader genome accessibility to transform cells.
In this study, we have shown that: 1) activated BRK regulates TGF-β/SMAD signaling by interacting with SMAD2/3 and 4; however, SMAD4 is the preferred target of BRK as shown by the results of competitive binding (Figure 2) ; 2) activated BRK phosphorylates SMAD4 on Tyrosines 353 and 412 (Figure 3) ; 3) BRK-mediated phosphorylation of SMAD4 rearranges its protein interaction networks (Figures 5-6) ; notably, phosphorylated SMAD4 is the target of ubiquitin/deubiquitin ligases and is degraded by the ubiquitin-proteasome pathway (Figures 5-6 ).4) the phosphorylation-regulated degradation of SMAD4 correlates well with the observation that BRK and SMAD4 show inverse expression patterns at the protein levels in breast cancer cells and tumors (Figure 4) ; 5) activated BRK modulates SMAD4 to suppress the tumor suppressor FRK, reduces the interaction of SMAD4 with cell adhesion molecules, and induces EMT (Figure 7) . Our study provides experimental evidence that the cellular role of SMAD4 is contextual and depends on other regulatory molecules such as the BRK kinase.
BRK is expressed in most of the cancer types (Figure 1A) . Although the expression of BRK is ubiquitous in most breast cancer cells and tumors, activated BRK was only detected in the plasma of breast tumors 24 . Thus, in this study, we focused on characterizing activated BRK and its role in signal transduction pathways. A kinome array 14 was used to uncover the signal transduction pathways regulated by activated BRK in cancer and normal cells. Ectopically expressed activated BRK regulates the TGF-β/SMAD signaling pathways by interacting with SMAD2/3 and SMAD4. However, SMAD4 outcompetes both SMAD2 and SMAD3 in a binding assay for activated BRK. The BRK modular SH3 domain mediates its protein-protein interactions to regulate signaling 49 . Of note, the SMAD4 activation domain (SAD) is proline-rich and contains the Pro-X-X-Pro motif 50 , which is the recognition site for SH3 domain 51 . However, our domain truncation data indicate that activated BRK interacts with an MH1 domain of SMAD4, which does not contain the SH3 recognition motif, suggesting that the Pro-X-X-Pro motif might be dispensable for SH3-mediated protein-protein interactions.
Intriguingly, we discovered that activated BRK-YF, but not wildtype BRK, phosphorylates tyrosines 353 and 412 on SMAD4 and reorganizes SMAD4 protein interaction and signaling networks. It was previously thought that the function of SMAD4 was regulated by ubiquitination but not by phosphorylation 36 . Recently, SMAD4 has been shown to be regulated and phosphorylated (on Thr277) by GSK3 52 . Additionally, our evidence reveals that BRK or other protein tyrosine kinases (since protein tyrosine kinase are functionally redundant 53 ) mediates phosphorylation of SMAD4, which is required for SMAD complexes to interact with chromatin remodelers such as SWI/SNF, mediator, HATs, or SIN3/HDAC complexes for gene regulation 18, 19 . In the absence of activated BRK, SMAD4 does not interact with SWI/SNF, HATs, or SIN3/HDAC complexes. Additionally, our data also reveal that tyrosine phosphorylated SMAD4 interacts with several other complexes including NuRD, ESC/E(Z), and spliceosomal complexes (Suppl. Figure 8 A&B) . Our data show that, unlike ubiquitination, activated BRK-mediated phosphorylation of SMAD4 also regulates SMAD4 function.
Complete loss or mutation in SMAD4 has been reported in several cancer types including pancreatic, cholangiocarcinoma, and colorectal cancer 54 . Additionally, SMAD4 protein levels decline concurrently with the cumulative malignancy of the tumor cells 55 . However, our data demonstrate differential expression of SMAD4 and BRK in a panel of breast cancer cell lines.
Interestingly, an inverse pattern of SMAD4 and BRK protein levels was noticed in HER2+ (HCC1428 and SKBR3) and TNBC (MDA MB 231, BT20, Hs578T, BT549 and HCC1954) cells, but not ER+ cells (T47D, MCF7, and BT474). However, there are no discrepancies in the expression of SMAD4 and BRK at the mRNA level in those cell lines, indicating a posttranscriptional mechanism of regulation of the protein levels. We also found that the inverselycorrelated pattern of expression between SMAD4 and BRK in patients' breast tumor tissues. In agreement with what is observed in TNBC cells, patients breast tumor samples also show higher levels of the BRK protein in comparison to SMAD4. Furthermore, cells stably expressing activated BRK show a drastic suppression of SMAD4 protein levels. We confirmed that p21, a known downstream target of SMAD4 19 , is indeed suppressed in these cell lines expressing activated BRK. However, SMAD4 was not restored or upregulated in MCF7 cells where BRK was knocked-down. This suggests that SMAD4 escapes being targeted for proteasomal degradation, which could be due to a mutation or post-translational modification of SMAD4 or inactivation of BRK in MCF7 cells.
Dupont et al. previously found that a cycle of ubiquitination and de-ubiquitination
regulates the function and protein-protein interaction of SMAD4: Ecto/TIF1γ-mediated monoubiquitination disassembles SMAD4 from the SMAD complex, while deubiquitination by FAM/USP9x allows SMAD4 to return to SMAD signaling pool 37 . Interestingly, our MudPITproteomics data revealed that BRK-phosphorylated SMAD4 interacts with several ubiquitin and deubiquitin ligases such as HERC2, RNF138 (ubiquitin ligases) and USP32, USP7, USP9X (deubiquitinases). When phosphorylated by activated BRK, SMAD4 becomes a target of ubiquitin ligases (HERC2 and RNF138), which accelerates its degradation by the ubiquitinproteasome pathway. However phosphorylated SMAD4 also becomes a target of deubiquitin ligases (USP32, USP7, USP9X). In fact, deubiquitin ligase USP9X shows a stronger affinity for tyrosine phosphorylated SMAD4 than non-phosphorylated SMAD4. Thus, we propose that activated BRK phosphorylates SMAD4 hence regulating its function by turning it into an oncogene, while cells defense mechanisms clear phosphorylated SMAD4 by the ubiquitinproteasome system. Activated TGF-β/Smad4 signaling has recently been shown to induce EMT, which triggers apoptosis in pancreatic cancer cells. SMAD2/3 binds with SMAD4 and translocates into the nucleus to the SNAIL mesenchymal marker locus to induce SNAIL expression 20 . Our data indicate that SMAD4 binds in the promoter region and promote FRK expression. However, in the presence of activated BRK, FRK expression is repressed in TNBC cells. Interestingly, overexpression of SMAD4 restores the BRK-induced suppression of FRK level in the TNBC cells stably expressing BRK. Previous studies have shown that the expression of SNAIL is upregulated in FRK-knocked down breast cancer cells 43 . We observed that activated BRK induces SLUG and SNAIL expression, while overexpression of FRK significantly suppresses the mesenchymal marker SLUG, suggesting an FRK-dependent mechanism for BRK induced promotion of EMT. Finally, 98% of 456 cases of breast carcinomas express SMAD4 56 , suggesting that activated BRK controls the function of SMAD4 by rearranging its protein interaction networks to allow a wide access to the genome, hence switching SMAD4 behavior from that of a tumor-suppressor to that of an oncogene (Figure 8) .
In summary, we provide additional evidence to counter the long-standing idea that SMAD4 is not regulated by phosphorylation. We have found that activated BRK competitively binds SMAD4 and regulates TGF-β/SMAD signaling pathways. Additionally, activated BRK suppresses cell homeostasis, cell cycle, and apoptotic signaling pathways and upregulates several oncogenic signaling cascades in a SMAD4-dependent manner. Activated BRK phosphorylates SMAD4 and hence reorganizes SMAD4-associated protein-protein interactions. Phosphorylated SMAD4 interacts with chromatin-modifying complexes and transcription factors, which provide access to a wide range of genes. Activated BRK also reduces cell adhesion ability and induces EMT in a SMAD4-dependent manner. Thus, the cellular role of SMAD4 is contextual, suggesting that personalized medicine would be necessary to combat SMAD4-associated tumors.
Material and Methods
Antibodies and reagents. The following antibodies were obtained from Santa Cruz All plasmid constructs were confirmed by sequencing. The primers were used for cloning and PCR were listed in the supplemental Table 7 . 
Generation of stable cell lines. The construction of cell lines stably expressing GFP-BRK-

MudPIT analysis for identification of SMAD4 associated proteins and protein complexes.
MudPIT Analysis for protein complexes identification was previously described in detail by Banks et al. 28 . Briefly, trichloroacetic acid (TCA) precipitated purified proteins were proteolytically digested with endoproteinase Lys-C followed by trypsin digestion, overnight at 37 ° C. A 10-step MudPIT separation approach was applied, and digested peptides were injected directly into a linear ion trap (LTQ) mass spectrometer where spectra were collected and identified. Peptide mass spectra were analyzed by using the ProLuCID 58 and DTASelect 59 algorithms. Next, we used Contrast 59 and NSAF7 60 software to rank the putative affinity purified proteins according to their distributed normalized spectral abundance values (dNSAF) 60 . We then used QSPEC 61 to identify enriched proteins in experimental samples compared to control samples. Benjamini and Hochberg statistical method 62 was used to calculate false discovery rates (FDRs) from QSPEC parameters suitable for multiple comparisons. Each of the experiments was repeated at least twice unless otherwise stated. The location of all mass spectrometry runs conducted in this work is described in Supplemental Table 8 and Supplemental Table 9 contains the results of the all affinity purifications followed by protein mass spectrometry analysis.
Luciferase reporter assays. FRK promoter and SMAD4 plasmids were cotransfected in HEK 293 cells using ViaFect TM (Promega Corporation, Madison, WI) according to the manufacturer's guidelines. In brief, 125,000 HEK 293 cells were seeded with 500 µl fresh media in each well.
The HEK 293 cells were co-transfected with FRK promoter (495 ng; Firefly Luciferase) along in each well. dH2O was added in each well to make the volume of 10 μL. Probes for target genes and housekeeping genes were labeled with FAM™ and VIC™ dyes, respectively. The expression of both genes was measured within the same well by using an Applied Biosystems™,
Step One Plus qRT-PCR machine (Life Technologies, Burlington, ON, Canada).
Cell Adhesion assay. 96 well plates were coated with either fibronectin or collagen I for an hour at 37°C followed by an hour incubation with 0.5% BSA containing blocking buffer. HEK 293 or MCF10A cells were seeded at a density of 4 × 10 5 and cells were allowed to attach for 45 minutes at 37°C. The cells were washed three times with 0.1% BSA containing culture media; then the cells were fixed with 4% paraformaldehyde. Next, the cells were stained with crystal violet for 10 minutes. After staining, the cells were washed with distilled water for 10 times.
Cells were air dried for an hour and solubilized with 2% SDS on an agitator. The absorbance of each well was measured at 550 nm to quantify the adhesion properties of cells.
Statistical Analysis. For multiple comparisons (qPCR and adhesion assay), One-way ANOVA followed by a post hoc Newman-Keuls test were used by using GraphPad Prism version 5.04, GraphPad Software, San Diego California USA, www.graphpad.com. The results are presented as the mean ± SD, n≥3 unless otherwise stated. P≤0.05 was considered statistically significant.
Data Availability Statement
Original data underlying this manuscript can be accessed from the Stowers Original Data Repository at http://www.stowers.org/research/publications/LIBPB-1340. The mass spectrometry datasets generated for this study are available from the Massive data repository (https://massive.ucsd.edu) under the identifier MSV000082858. Data can be accessed using ftp://MSV000082858@massive.ucsd.edu and the password: MWLab. Y353F & Y412F, with or without SNAP-Flag-BRK-YF were co-transfected into HEK293T cells and the cell lysates were subjected to affinity purification followed by immunoblotting with anti-PY20 or anti-SMAD4 antibodies. The expression of Halo-SMAD4, Halo-SMAD4 Y353F & Y412F, and SNAP-Flag-BRK-YF were analyzed by immunoblotting by using anti-Halo and anti-Flag specific antibodies. β-tubulin was used as a loading control. Figure 8 
